Broad Institute has announced that the patents granted to MIT, Harvard and Broad Institute concerning CRISPR editing of eukaryotic genomes do not interfere with patent claims filed by UC Berkeley and the University of Vienna, according to a decision handed down by the U.S. Patent Trial and Appeal Board on February 15. The decision confirms […]

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing of ABP 501, a biosimilar for Abbvie’s Humira (adalimumab). The committee recommended approval for all available indications, including moderate-to-severe rheumatoid arthritis, chronic plaque psoriasis, Crohn’s disease and ulcerative colitis. ABP 501 is the first Humira […]

Takeda Pharmaceuticals has announced it will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, for a total value of approximately $5.2 billion. The transaction is expected to close by the end of February 2017. The acquisition of Cambridge-based ARIAD adds new investigational oncology products to Takeda’s pipeline, including Brigatinib […]